Target intelligence / Profile preview

Nociceptive transmission-associated neurotransmitter

Molecular classification
Neuropeptide, Amino acid neurotransmitter, Biogenic amine, Receptor ligand
01

Overview

Nociceptive transmission-associated neurotransmitters refer to a group of chemical messengers, primarily excitatory neuropeptides and amino acids, that facilitate the transmission of pain signals from peripheral nociceptors to the central nervous system. Key members include glutamate, the primary excitatory neurotransmitter, and neuropeptides such as Substance P, Calcitonin Gene-Related Peptide (CGRP), and Cholecystokinin (CCK). These molecules are released from the central terminals of primary afferent fibers, such as A-delta and C fibers, into the dorsal horn of the spinal cord or the trigeminal nucleus caudalis. In chronic pain conditions or migraine, the pathological upregulation of these neurotransmitters leads to increased neuronal excitability and central sensitization. Therapeutic interventions targeting this category involve inhibiting their release (e.g., via opioids or triptans) or antagonizing their respective receptors (e.g., CGRP or NK1 receptors) to alleviate pain and restore normal sensory processing.

Other names
Nociceptive neurotransmittersPain-transmitting neurotransmittersPro-nociceptive chemical messengersExcitatory neurotransmitters of the dorsal horn
02

Mechanism of action

Inhibition of neurotransmitter release from presynaptic terminals (e.g., via 5-HT1B/1D or opioid receptor activation) and antagonism of postsynaptic receptors (e.g., NK1, CGRP, or NMDA receptors) to block the propagation of noxious stimuli.

03

Biological functions

Signal transductionNociceptionPeripheral and central sensitizationNeurogenic inflammationSynaptic transmission
04

Disease associations

Chronic painMigraineNeuropathic painInflammationFibromyalgia
05

Safety considerations

Off-target central nervous system effects (sedation, cognitive impairment)Cardiovascular risks associated with CGRP modulationDevelopment of tolerance and physical dependence (opioid-related)Gastrointestinal disturbances
06

Interacting drugs

Sumatriptan

5 more in the full profile.

07

Biomarkers

CGRP levels in peripheral blood or plasmaSubstance P levels in cerebrospinal fluid (CSF)Glutamate concentration in the dorsal horn (imaging/preclinical)c-Fos expression in the trigeminocervical complex

Beyond the preview

Go deeper on Nociceptive transmission-associated neurotransmitter.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nociceptive transmission-associated neurotransmitter.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call